Description
Indication & Scope
Olaparib Tablets (Lynparza®) is a potent oral PARP inhibitor. It blocks PARP-mediated DNA single-strand break repair, inducing synthetic lethality in tumor cells with defective homologous recombination repair (BRCA/HRD mutation) and inhibiting tumor proliferation.
- Mechanism
Poly (ADP-ribose) polymerase (PARP) inhibitor - Drug class
Prescription oral targeted anticancer drug - Clinical use
HRD/BRCA-mutated ovarian, breast and prostate cancer
| Generic Name | Olaparib Tablets |
| Brand Name | Lynparza® |
| Ingredient | Olaparib |
| Dosage Form | Film-coated Tablets |
| Package | 150mg*56 tablets/box |
| Conditions Treated | Maintenance treatment for adults with BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer after first-line platinum chemotherapy response. Metastatic BRCA-mutated HER2-negative breast cancer |
| Taboos | Pregnant and breastfeeding women; Patients hypersensitive to olaparib or any excipients |
| Place of origin | Puerto Rico, United States; Gärtunavägen Södertälje, Sweden |
| Priscription Type | Prescription Drug |
| Storage Conditions | Sealed, store below 30°C, protected from light |
| Manufacturer | AbbVie Limited; AstraZeneca AB |
| Registration Authority | National Medical Products Administration (NMPA) |
| Approval number | HJ20180049 |
| Approval Date | December 25, 2024 |
| Shelf Life | 36 months |
How to use ?
Recommended Dose: Standard dosage regimen: 300 mg orally twice daily (150mg × 2 tablets each time). Take continuously until disease progression or intolerable toxicity.
Time: Fixed twice daily oral administration, taken with or without food.
Interaction: Strong CYP3A4 inhibitors significantly increase olaparib exposure, dose reduction is mandatory. Strong CYP3A4 inducers reduce drug efficacy, concurrent use forbidden.
Side effects: Common reactions: Anemia, neutropenia, thrombocytopenia, fatigue, nausea, vomiting, diarrhea, arthralgia, headache. Long-term risks: Myelodysplastic syndrome/acute myeloid leukemia, pneumonitis, elevated creatinine. Rare severe adverse events: Severe hypersensitivity, venous thromboembolism.
Important Notice
This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is the core pharmacological classification of olaparib?
Oral PARP inhibitor targeting DNA damage repair.
Until when should patients continue olaparib maintenance treatment?
Continuous twice-daily administration until tumor progression or unendurable toxicity.
What fatal rare adverse event should patients report immediately?
New or worsening cough/dyspnea suggestive of pneumonitis.
Does food affect olaparib absorption?
No, patients can take tablets before or after meals.
Lynparza® | Olaparib Tablets | Epithelial Ovarian Cancer | DengYueRX
INN: Olaparib
Indications: Epithelial Ovarian Cancer
Dosage Form: Film-coated Tablets
Strength: 150mg/Tablet
Original price was: $887.04.$753.98Current price is: $753.98.
